Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 2016. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibilities (PDMRs) in accordance with DTR 3.1.4R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details.
- Transaction Type: Acquisition of American Depositary Shares (ADSs) via dividend re-investment.
- Dividend Date: January 14, 2016.
- Transaction Price: $38.69 per ADS.
Material Changes
The filing details specific changes in shareholdings for the following individuals following the dividend re-investment:
| Director/PDMR | ADSs Acquired |
|---|---|
| Dr M M Slaoui | 1,895.907 |
| Mr N Hirons | 238.022 |
| Mr D E Troy | 1,086.669 |
| Dr K Slaoui (Connected Person) | 83.554 |
GSK was informed of these allocations on January 28, 2016.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of insider trading activity rather than a financial performance report.
Investor Verification Points
- Verify the total number of ADSs acquired by directors and connected persons during the dividend re-investment period.
- Confirm the transaction price of $38.69 per ADS aligns with market prices on January 14, 2016.
- Review the full list of PDMRs to ensure all required disclosures under DTR 3.1.4R are complete.